Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
22nd February 2021 | Jason Ehrlich | 1,611 | Open or private sale | $125.97 | $202,940.73 |
22nd February 2021 | Jason Ehrlich | 2,150 | Open or private sale | $124.92 | $268,573.92 |
22nd February 2021 | Jason Ehrlich | 413 | Open or private sale | $129.18 | $53,349.61 |
22nd February 2021 | Jason Ehrlich | 1,827 | Open or private sale | $127.34 | $232,650.36 |
22nd February 2021 | Jason Ehrlich | 262 | Open or private sale | $122.00 | $31,963.66 |
22nd February 2021 | Jason Ehrlich | 687 | Open or private sale | $123.56 | $84,888.61 |
22nd February 2021 | Jason Ehrlich | 6,950 | Exercise of derivative | $10.29 | $71,515.50 |
17th February 2021 | Bros. Advisors Lp Baker | 5,792,538 | Open or private purchase | $16.00 | $92,680,608.00 |
17th February 2021 | Bros. Advisors Lp Baker | 457,462 | Open or private purchase | $16.00 | $7,319,392.00 |
20th January 2021 | Jason Ehrlich | 2,061 | Open or private sale | $163.10 | $336,139.21 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company. The company engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; K SI-501 for DME and uveitis.
10th February 2021
25th January 2021
11th January 2021